iCAD Expands Access to the Xoft System for Treating Non-Melanoma Skin Cancer to Dermatology Centers via a Strategic Alliance

  iCAD Expands Access to the Xoft System for Treating Non-Melanoma Skin Cancer
  to Dermatology Centers via a Strategic Alliance With DermEbx

Business Wire

NASHUA, N.H. -- September 11, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced a strategic alliance
with DermEbx™ to offer the Xoft^® Axxent^® Electronic Brachytherapy System^®
to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of
dermatology centers. DermEbx currently services 14 locations in Arizona,
California and Nevada with Xoft System units placed in all locations.

“We are pleased to provide patients diagnosed with non-melanoma skin cancer
this innovative and effective treatment option that is administered in their
dermatologist’s office under the supervision of a radiation oncologist,” said
Ken Ferry, iCAD’s CEO. “Electronic brachytherapy is a proven, non-invasive
alternative to surgery, and this strategic alliance will allow us to expand
the number of systems we have in place to treat more patients at centers
managed by DermEbx. This agreement provides patients with a proven, convenient
treatment alternative in a familiar care environment.”

“We are excited to bring the Xoft System to our managed centers as part of
this strategic alliance,” said Kamal Gogineni, President of DermEbx. “The
collaboration between DermEbx, dermatologists and its affiliated radiation
oncologists will help create a comprehensive solution for this advanced
technology in treating skin cancer patients.”

“DermEbx integrates the mobile Xoft System into its dermatology centers by
allowing treatment to occur in the facility where the diagnosis is made,
potentially eliminating the need to visit multiple service providers at
different locations,” said David Berman, M.D., Medical Director, Berman
Gladstone Skin Institute. “The mobility of the Xoft System enables a radiation
oncologist to treat more patients at multiple dermatology centers.”

About Non-Melanoma Skin Cancer

NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is
not only the most common type of skin cancer, it is the most common type of
cancer in humans. These cancers commonly appear on sun-exposed areas of the
body such as the face, ears, neck, lips and backs of the hands. NMSC affects
approximately 2.2 million Americans each year.

About Xoft Axxent ^  Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early stage breast cancer, endometrial
cancer, cervical cancer and skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. Xoft is a
wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit

About DermEbx

Founded in January 2013, DermEbx is a leading healthcare services and
technology company dedicated to offering skin electronic brachytherapy
programs to Dermatology and Oncology Networks. This program includes
collaboration with clinical care teams and management staff in successfully
integrating equipment and software into a patient-centric workflow model.
DermEbx helps its customers with scalability and operational efficiencies in
delivering programs that meet quality and standards for improved patient care.
For more information, call 408-625-7710 or visit www.dermEbx.com.

About iCAD, Inc.

iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in
the form of intraoperative radiation therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of non-melanoma
skin cancer, cervical cancer and endometrial cancer. For more information,
call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at

Photos/Multimedia Gallery Available:



For iCAD
Kevin Burns, 937-431-7967
For iCAD investor relations
Anne Marie Fields, 212-838-3777 x6604
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
Press spacebar to pause and continue. Press esc to stop.